Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IDIBELL and VHIR licenses Histocell a Patent for Acute Respiratory Diseases with Stem Cells

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
It is a "smart drug" that can reduce inflammation and regenerate damaged tissue.

The product has given good results in animals to treat acute respiratory distress and some forms of asthma and could be effective for other acute or chronic lung diseases.

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells. These cells, administered intravenously, have the ability to go directly to the damaged lungs, acting as a "smart drug".

To enhance the effect, researchers have modified this cells by genetic engineering. The studies have been developed by a team led by Josep Maria Aran, researcher at the Human Molecular Genetics group of IDIBELL, with researchers of the Pneumology group at Vall d'Hebron Research Institute (VHIR) and the Biomedical Research Network Centre for Respiratory Diseases (CIBERES). The outcomes of the research have supposed an international patent application managed by the Technology Transfer Office (TTO) at IDIBELL.

The researchers use adult mesenchymal stem cells extracted from adipose tissue obtained from liposuction. These cells are capable of enhancing the regeneration of the damaged lung tissue and secrete inflammatory proteins therein when injected into the blood.
Improvements

The novelty patented by IDIBELL, VHIR and CIBERES researchers has been the insertion of improvements through genetic engineering that can significantly enhance the anti-inflammatory and regenerative power of the mesenchymal cells. Specifically, researchers have modified the antagonist to secrete interleukin 33, a regulatory protein (cytokine) that has a fundamental role in the inflammatory process.

The treatment has proven to be very effective given intravenously, although it could be considered the option of administering it by inhalation.

In the administered dose, these stem cells do not involve immune rejection, because the body removes them after their function is performed. This makes them particularly useful for treating acute diseases.

Good results

The licensed product to Histocell has been successful in experiments on animals with acute respiratory distress, a very severe respiratory failure without effective treatment. It has also been proven effective in animal models with allergic asthma to persulfate salts, a condition equivalent to a professional disease detected among professional hairdressers. The researcher Josep Maria Aran stresses that the new technology could also have applications in other acute and even chronic conditions such as emphysema.

In any case, many years will be needed before the product can be applied in humans. It will require additional preclinical studies and clinical trials in people. In this sense, the patent licensed to Histocell is essential to complete these studies and bring the product to market.

Get to market

The head of the TTO at IDIBELL, Montse Ballarín, highlights the fact that "the licensed products developed at our institution reflect the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market and, ultimately, to develop products at the service of society”.

Histocell is a biopharmaceutical company based in the Basque Country (Spain) specialised in tissue engineering and in cell therapy. The company is dedicated to developing innovative products in the field of regenerative medicine. It has a cleanroom for developing cell therapy products based on tissue engineering. The company has four therapeutic programs: bone and joint regeneration, neuroprotection in spinal cord injury and pulmonary therapy.

The development of the patent transferred to Histocell has been possible thanks to the funding of the Spanish Ministry of Economy and Competitiveness, the Instituto de Salud Carlos III and the European funds for regional development (ERDF).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Keeping Growth in Check
Ribosomal proteins RPL5 and RPL11 play an essential role in normal cell proliferation.
Friday, December 13, 2013
Key Role of a Protein in the Segregation of Genetic Material During Cell Division
Researchers at IDIBELL have reported an article which delves into the regulator mechanisms of mitosis.
Wednesday, December 11, 2013
Discovered a Mechanism that Induces Migration of Tumor Cells in Liver Cancer
Coordinated overactivation of TGFb and CXCR4 signaling pathways confer migratory properties to the hepatocellular carcinoma cells.
Wednesday, November 06, 2013
The European Union Allocates Six Million Euros to Study Prevention Strategies Tumors Caused by HPV
The human papillomavirus (HPV) is responsible for cervical cancer and is behind a significant percentage of other tumors such as vulva , vagina, penis, anus, and oropharynx.
Tuesday, November 05, 2013
Researchers Discover the Genetic Signature of Highly Aggressive Small Lung Tumors
A study conducted by the IDIBELL allows to identify this type of cancer at an early stage and adapt the treatment.
Thursday, October 03, 2013
Discovered Epigenetic Alterations in the Brain of Alzheimer's Patients
Alzheimer disease is becoming a major health problem in Western societies, exacerbated by the progressive aging of the population.
Monday, September 16, 2013
High Levels of RANK Protein Interferes with the Differentiation of Mammary Cells
Levels of this protein increase with age, which could explain the increase in breast cancer risk associated with age.
Wednesday, September 11, 2013
The Epigenome Differentiates the Different Human Populations
Establishing what differentiates us from our neighbors, our friends or strangers from distant countries.
Monday, August 05, 2013
Patented, a Molecule that Opens the Door to Develop New Drugs Against Immune Rejection
Researchers have patented a peptide that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs.
Thursday, August 01, 2013
Discovered a Future Therapeutic Target for Lung Cancer Treatment
One of the goals of research in cancer genetics and molecular biology is to get an "on demand" treatment, with maximum effect and minimal toxicity.
Monday, July 22, 2013
Brain Epigenome Changes from Birth to Adolescence
Experience of parents with their children and teachers with their students demonstrate how kids change their behaviours and knowledge from childhood to adolescence.
Friday, July 05, 2013
Discovered the Role of Noncoding 5S rRNA in Protecting the p53 Tumor Suppressor Gene
Over 50% of tumors are associated with mutations in p53.
Thursday, July 04, 2013
A Gene Conserved from Worms to Humans Opens the Door to new Therapeutics
Gene shows promising therapeutic strategies in cancer and in some types of blindness.
Friday, June 21, 2013
Genetically Modified Stem Cells are Effective Against Acute Respiratory Diseases
Administration of genetically modified mesenchymal stem cells regenerates lung tissue and stops the inflammatory process in mice with acute lung injury.
Tuesday, June 18, 2013
An Epigenetic Change Causes the Block of Antitumor Genes
Healthy cells live in a delicate balance between growth-promoting genes (oncogenes) and those who restrain it (anti-oncogenes or tumor suppressor genes).
Wednesday, June 12, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!